secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001999371-25-004974
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Tonix Pharmaceuticals Presents Positive Preclinical Data on TNX-1700 for Gastric Cancer at AACR 2025
--------------------------------------------------------------------------------

- At AACR 2025, Tonix showed TFF2-MSA (murine TNX-1700) plus anti-PD1 inhibited gastric tumor growth by 78.29% in mouse models.
- Combination therapy activated cancer-killing CD8+ T cells and reduced immunosuppressive PMN-MDSCs in the tumor microenvironment.
- TNX-1700 (hTFF2-HAS) is in preclinical development for gastric and colorectal cancers, with further studies planned.
- Data demonstrated TFF2-MSA outperformed CXCR4 antagonist AMD3100 in reducing PMN-MDSC generation.
- TFF2 reduction correlated with elevated PMN-MDSCs in gastric cancer patients, supporting the therapeutic target.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125004974/0001999371-25-004974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125004974/tnxp-8k_042925.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-004974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer